These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 29268035

  • 1. Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.
    Kadowaki T, Haneda M, Ito H, Ueno M, Matsukawa M, Yamakura T, Sasaki K, Kimura M, Iijima H.
    Expert Opin Pharmacother; 2018 Feb; 19(2):83-91. PubMed ID: 29268035
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T, Haneda M, Ito H, Sasaki K, Yamada Y.
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [Abstract] [Full Text] [Related]

  • 3. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
    Kadowaki T, Haneda M, Ito H, Sasaki K, Matsukawa M, Yamada Y.
    Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
    [Abstract] [Full Text] [Related]

  • 4. Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
    Kadowaki T, Haneda M, Ito H, Sasaki K, Hiraide S, Matsukawa M, Ueno M.
    Adv Ther; 2018 Jun; 35(6):817-831. PubMed ID: 29777520
    [Abstract] [Full Text] [Related]

  • 5. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
    Kadowaki T, Inagaki N, Watada H, Sasaki K, Mori-Anai K, Iwasaki T, Teranishi T.
    Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.
    Goda M, Yamakura T, Sasaki K, Tajima T, Ueno M.
    Curr Med Res Opin; 2018 Feb; 34(2):319-327. PubMed ID: 29025285
    [Abstract] [Full Text] [Related]

  • 11. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
    Inagaki N, Nangaku M, Sakata Y, Sasaki K, Mori-Anai K, Iwasaki T, Hamada K.
    Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
    Terauchi Y, Yokote K, Nakamura I, Sugamori H.
    Expert Opin Pharmacother; 2016 Jan; 17(4):463-71. PubMed ID: 26800061
    [Abstract] [Full Text] [Related]

  • 14. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T, Kondo K.
    Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
    Otsuki H, Kosaka T, Nakamura K, Shimomura F, Kuwahara Y, Tsukamoto T.
    Int Urol Nephrol; 2014 Feb; 46(2):427-32. PubMed ID: 24014134
    [Abstract] [Full Text] [Related]

  • 16. Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study.
    Maegawa H, Tobe K, Nakamura I, Uno S.
    Curr Med Res Opin; 2019 Nov; 35(11):1901-1910. PubMed ID: 31347926
    [Abstract] [Full Text] [Related]

  • 17. Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study.
    Yoshikawa K, Tsuchiya A, Kido T, Ota T, Ikeda K, Iwakura M, Maeda Y, Maekawa S.
    Adv Ther; 2020 May; 37(5):2442-2459. PubMed ID: 32306246
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.